Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Last trade$43.25
Day change-$0.445 (-1.02%)
Day range$43.03 – $44.01
Volume6,619,133
Market cap$63.33B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$63.33B
Price / earnings
18.08×
Price / book
2.47×
Price / sales
3.01×
EV / sales
3.54×
EV / EBITDA
12.54×
Profitability
Earnings per share
$2.42
Return on assets
7.7%
Return on equity
13.66%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.47×
Current ratio
1.36×
Quick ratio
0.81×
Cash ratio
0.1×
Cash flow
Price / cash flow
14.96×
Price / free cash flow
19.01×
Free cash flow
$3.33B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BSX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$5.14B
$5.44B
$5.2B
$5.29B
$5.07B
$5.06B
$4.66B
$4.56B
Cost of revenue
$1.71B
$1.59B
$1.59B
$1.61B
$1.52B
$1.64B
$1.45B
$1.47B
Gross profit
$3.43B
$3.85B
$3.61B
$3.68B
$3.54B
$3.42B
$3.21B
$3.1B
Selling, general and administrative
$1.68B
$1.8B
$1.78B
$1.83B
$1.74B
$1.72B
$1.6B
$1.61B
Research and development
$520M
$554M
$516M
$569M
$514M
$526M
$443M
$459M
Total operating expenses
$2.6B
$2.67B
$2.51B
$2.85B
$2.49B
$2.61B
$2.29B
$2.42B
Operating income
$828M
$1.18B
$1.1B
$825M
$1.05B
$819M
$921M
$675M
Interest expense
-$100M
-$96M
-$90M
-$90M
-$87M
-$90M
-$82M
-$80M
Income before taxes
$733M
$1.06B
$1.16B
$700M
$939M
$941M
$805M
$585M
Income taxes
$153M
$155M
-$176M
$30M
$183M
$146M
$133M
$23M
Net income
$580M
$905M
$1.34B
$670M
$756M
$795M
$672M
$562M
Net income attributable to common shareholders
$582M
$907M
$1.34B
$672M
$755M
$797M
$674M
$565M
EBITDA
$1.37B
$1.62B
$1.43B
$1.53B
$1.39B
$1.32B
$1.34B
$1.19B
Basic earnings per share
$0.40
$0.62
$0.90
$0.45
$0.51
$0.54
$0.46
$0.38
Diluted earnings per share
$0.40
$0.61
$0.90
$0.45
$0.51
$0.53
$0.45
$0.38
Recent news
Company coverage with links to the original publishers.
The global nerve repair and regeneration market is projected to grow from USD 10.65 billion in 2025 to USD 20.97 billion by 2031, expanding at an 11.96% CAGR. Growth is driven by rising nerve injuries, advances in neurostimulation technologies, and biomaterial innovations. Neurostimulation devices currently dominate with 58.74% market share, while biomaterials are the fastest-growing segment at 14.01% CAGR. High implant costs and cybersecurity risks remain challenges, with Asia-Pacific expected to record the fastest regional growth.
Boston Scientific (BSX) lowered its 2026 sales growth forecast to 4.25% and adjusted EPS guidance to $3.16-$3.18 due to unexpected headwinds in its WATCHMAN and Electrophysiology franchises. WATCHMAN organic sales fell 5.9% amid weakening demand, while Electrophysiology declined 5.3% due to competitive pressure from Pulsed Field Ablation technologies. The company faces additional challenges from delayed product launches, elevated debt levels, and a cybersecurity incident that accelerated competitive share losses. BSX shares have declined 53.5% year-to-date, significantly underperforming peers and the broader market.
Coherent (COHR) was named Bull of the Day after delivering strong Q1 results with 50% revenue growth, 80% EPS growth, and raised long-term gross margin targets, driven by AI datacenter demand. Boston Scientific (BSX) was named Bear of the Day as it continues to face weak growth outlook with flat 2027 EPS estimates and declining analyst forecasts. CoreWeave (CRWV) reported record Q3 revenues of $3.66B with a $132.5B backlog but faces concerns over high debt levels and mounting interest expenses.
Boston Scientific reported Q3 organic sales growth of 1.5% that missed guidance due to a cybersecurity disruption, with adjusted EPS falling 3% to 73 cents. The company cut 2026 sales and earnings forecasts, and consensus EPS estimates for 2025 and 2026 have been lowered significantly. Management expects 2027 to be the cycle's trough with recovery anticipated in 2028 driven by new product launches.
Boston Scientific's WATCHMAN left atrial appendage closure device continues to face declining demand despite positive clinical trial results and expansion efforts. The company expects low-single-digit sequential sales declines in Q3 2026 and assumes no market improvement in 2027, while competitors like Abbott and Edwards Lifesciences show stronger momentum in electrophysiology and structural heart segments.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.